Exscalate4cov is a public-private consortium supported by the European Commission’s Horizon 2020 tender for projects to counter the Coronavirus pandemic and improve the management and care of patients. At the core of Exscalate4CoV is Exscalate (EXaSCale smArt pLatform Against paThogEns), at present the most powerful and cost-efficient intelligent supercomputing platform in the world. Exscalate has a “chemical library” of 500 billion molecules and a processing capacity of more than 3 million molecules per second. The Exscalate4CoV consortium, coordinated by Dompé Farmaceutici (Italy), is composed by 18 institutions from seven European countries. Chelonia – the swiss leading player in translational science, communication & dissemination – is one of the member of the consortium. Last July 2020 the consortium, only in 3 months from start of the project, announced the finding of an existing osteoporosis drug (Raloxifene) showing potential for treating COVID-19. Now, in agreement with European Commission, the consortium is launching the most important crowdsourcing project ever: data generated by in-silico simulation and in-vitro analysis will be make freely available to the international scientific community for doing molecular docking at home and finding new therapeutic candidates against coronavirus.